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Responses to Revaccination with Type III Oral 
Poliovirus Vaccine. 
Introduction 
In 1954, the first large scale trial of formalinized polio- 
vims vaccine was a major "breakthrough in the eventual control of 
paralytic poliomyelitis.(l) Indeed, with the widespread use of mass 
immunization of the population in this country, the yearly rate of 
paralytic poliomyelitis has clearly "been reduced. Morbidity sta¬ 
tistics have shown that the number of paralytic poliomyelitis cases 
in the United States, which numbered approximately 15,000 annually 
during the period 19511*1955, dropped sharply between 1956 and 1959 
to approximately 5,100 cases per year.(2) However several epidemics 
in 1959 halted this steady decline of paralytic cases which had been 
observed between 195& and 1958* 
One of the most important reasons for the recent increase 
in clinical poliomyelitis is that the population at large has failed 
to utilize the available vaccines. 
Formalinized vaccines offer protection against the paralytic 
complication of a poliomyelitis infection by inducing the production 
of a type specific neutralizing antibody. However, it has been shown 
(3>^»5) that individuals having high levels of neutralizing antibody 
induced by formalinized vaccine, are still susceptible to alimentary 
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infection, with poliovirus,and such subjects exhibit prolonged fecal 
excretion of poliovirus. 
An inapparent natural infection with poliomyelitis virus, 
on the other hand, induces permanent protection against the para¬ 
lytic disease even though the neutralizing antibodies may be at a 
relatively low level(6)*When naturally immune individuals, particu¬ 
larly adults,(4) become reinfected, the period of fecal excretion 
of poliovirus is relatively short.(7,8) It has been suggested, 
therefore, that a local tissue factor in the epithelium of the 
intestinal tract of naturally immune individuals may play a role 
in protecting against reinfection. Efforts to produce a vaccine 
which would duplicate the natural processes of immunity without the 
risk of subsequent paralysis have led to numerous studies with both 
naturally occuring and experimentally produced attenuated strains of 
polioviruses. 
Koprowski et al. were the first to administer a live rodent 
adapted poliovirus to volunteers in 1950-(9) In 195^4 Sabin et al 
(10) found that polioviruses, after a number of rapid passages in 
monkey kidney tissue cultures and purification by the terminal di¬ 
lution method, could be rendered almost completely avirulent for 
monkeys. In 1955 Sabin tested these strains of attenuated poliovirus 
in chimpanzees and human volunteers (11,12) and found that they 
produced an inapparent alimentary infection, in bothji.e., without 
evidence of any associated paralysis. In these experiments the 
polioviruses which were recovered from the feces were found still to 
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"be avirulent when innoculated intracerebrally into monkeys. 
Koprowski et al. (13,14) fed attenuated types I and II 
poliovirus vaccines simultaneously to large numbers of nonimmune 
children and separately to a group of young infants. Hone of these 
subjects contracted clinical poliomyelitis and all developed homo- 
typic antibodies. Neither injections of gamma globulin nor the 
presence of passively transfered antibodies affected the course of 
the inapparent alimentary infection. 
Larger field trials with attenuated poliovirus vaccines 
ha.ve subsequently been conducted in various parts of the xtforld. 
Over 200,000 inhabitants of the Belgian Congo and Ruanda- 
Urundi were vaccinated with an attenuated type I poliovirus by 
Courtois et al. (16) in 1958. None of these individuals developed 
clinical poliomyelitis after the virus feeding. Subsequent to vac¬ 
cination of all community members during four different outbreaks 
of poliomyelitis, no new cases of paralysis were reported. 
Early in 1959 Sabin’s strains of poliovirus vaccines were 
used in mass vaccination programs in the U.S.S.R. (17) Approximately 
15,000,000 people were vaccinated and followed for a period of 6-9 
months. During at least this surveilance period the vaccines seemed 
safe both for the vaccinees and for their communities. 
The orally vaccinated republics experienced, during 1959, 
a marked reduction in paralytic cases, suggesting that the vaccine 
played a significant role in reducing the incidence of clinical 
poliomyelitis. In Tashkent vaccination was carried out in the midst 
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of an epidemic. The short duration, the sharp drop in cases of para¬ 
lysis, and the relative immunity of the vaccinated as to non-vaccinated 
children all suggest that the live vaccine modified the course of the 
epidemic. Subsequently, in the U.S.S.R., more than 70,000,000 people 
have received the oral poliomyelitis vaccine. The very low incidence 
of clinical poliomyelitis in I960 is encouraging. 
Further understanding of the immune mechanisms of polio¬ 
myelitis infections is of major concern at present. 
Experimental work in chimpanzees by Bodian et al. (18,19,20) 
and Howe (15,22) suggests that the level of serum neutralizing anti¬ 
bodies is of major importance in limiting the spread of ingested 
virus, and in high titers may even limit alimentary multiplication. 
In his earlier work Bodian et al. found that antibody alone could 
prevent viremia and paralysis after large amounts of peripherally 
innoculated poliovirus. The presence of such antibody, however, did 
not apparently affect fecal virus excretion nor did it prevent active 
antibody response subsequent to oral feeding of poliovirus. Since 
he found (23) large amounts of poliovirus in the tonsils and Peyer's 
patches but not in adjacent ileum of infected chimpanzees, Bodian 
postulated (2l) that poliovirus multiplication primarily occured in 
these lymphoid tissues and subsequently was blood-borne to other areas 
of the body including the central nervous system. This systemic 
spread of poliovirus, he believed, could be prevented by relatively 
low levels of circulating homotypic antibodies. 
On the other hand, Paul, Horstmann, (24) Beiderman, (25) 
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Sabin, (26) Fox (5) and others believe that while adequate levels 
of serum antibodies prevent or modify the paralytic complication of 
a poliomyelitis infection, the primary site of viral multiplication 
is the wall of the alimentary tract. As postulated by these workers, 
virus multiplication takes place within the superficial mucosal 
cells and/or the superficial lymphatics, the infective virus spread¬ 
ing from cell to cell until previously infected sites are encountered. 
Such an infection produces a local immunity which subsequently acts 
as a first line of defense in preventing reinfection with a horno- 
typic poliovirus. Massive amounts of virus, however, can overwhelm 
this type of local intestinal immunity. 
The present investigation is a continuation of studies of 
local immunity within the intestinal tract of man, which were begun 
by this department in 1956.(27) 
These studies were conducted in a group of mentally retarded 
children and young adults who live in close association in a "closed11* 
institutional environment. 
In the first trial, which was carried out in November, 1956* 
20 children, aged 4-24, were fed a large dose of the L Sc strain of 
type I poliovirus vaccine. Of these subjects, 10 had type I anti¬ 
bodies induced by killed virus vaccine (the V group), and 10 had anti¬ 
bodies from "X" number of previous type I polio infections (the N 
group). 
It was observed that the V individuals were much more read¬ 
ily infected than similar groups of IT individuals. This was evidenced 
*Th.e children rarely leave the cottage-like-dormitory in which they live. 
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"by prolonged virus excretion and sharp increases in neutralizing 
antibody levels of the V individuals, whereas the N subjects de¬ 
monstrated relatively brief fecal excretion of virus and generally 
insignificant antibody responses. 
On March of 1957* a second trial was initiated in which 
11 individuals were refed the same large dose of the L Sc type I 
poliovirus. It was observed that after one alimentary infection 
with an attenuated poliovirus the V group responded in a manner 
very similar to the N group$ i.e., they had shorter periods of 
fecal virus excretion and less striking antibody responses. 
The effect of dosage in reinfecting the alimentary tract 
was determined in a third trial in November 1957* Four groups of 
4 individuals were refed graded doses (ranging from ICK TCD50 to 
lO'-'*'"' TCD50) of the same type I poliovirus used previously. With, 
a high dose of virus most individuals, both N and Y, excreted 
significant amounts of virus and experienced at least a three fold 
increase in homotypic antibody titer. Lower doses of virus pro¬ 
duced only isolated episodes of fecal virus excretion with no 
associated antibody increase.,-see HOLE 5. 
In April of 1953 a fourth trial, (28) similar in most 
respects to the first trial with attenuated type I poliovirus, was 
carried out with Sabin’s KB-34 strain of type III attenuated polio¬ 
virus vaccine. A dose of 1CT TCD50 was fed a group of oil and 6V 
individuals, aged 6-11 years. Regardless of the original immune 
status or1 of the level of homotypic antibodies, all 12 individuals 
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excreted significant amounts of fecal virus and/or experienced a mark¬ 
ed antibody rise. Poliovirus excretion averaged 3 weeks in the U 
group and 5 weeks in the V group. Tables I and II compare these re¬ 
sults with those of the first type I trial. All V individuals fed 
type I attenuated jjoliovirus responded with a significant increase 
in antibody titer while only 2 of the 9 in the II group experienced 
a similar antibody response. In contrast, substantial antibody in¬ 
creases were apparent in 5/6 individuals in both the N and the ? 
groups following administration of type III poliovirus. The active 
immune response experienced by the naturally immune individuals fed 
the type III poliovirus suggested that immunity induced by an infection 
with type III poliovirus might in some way differ from that induced 
by an infection with the type I poliovirus. Furthermore, it was ob¬ 
served, when antibody responses are correlated with the number of 
positive stools (Tables I,II, and III), that the N subjects fed the 
type I poliovirus vaccine were' the only group which was not heavily 
infected during the first 10 post-feeding days. 
The present study is concerned with determining the immune 
responses in humans following a second feeding of Sabin's type III 
oral poliovirus vaccine. A titration type of trial in which graded 
doses of virus were fed was designed in an attempt to obtain quanti¬ 
tative data comparing, if possible, the ease of reinfectivity to the 
prefeeiiing homotypic antibody titer, and to measure the duration and 
amount of poliovirus excreted in the stools of both N and V individuals 
who have had one previous alimentary infection with the attenuated 
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TABLE 2 
INDIVIDUALS FED lO^TCDtf) CF SABINS TYPE III 
ATTENUATED POLIOVIRUS VACCINE, APRIL, 1958 
VACCINE IMMUNE NATURALLY IMMUNE 
collected 
S 
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v0 SUBJECT # 
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TABXE 3 
PREFEEDING ANTIBODY TITHE AND ANTIBODY INCREASE 
IN INDIVIDUALS FED EITHER SAB BPS TYPE I OR 
TYPE III ATTENUATED POLIOVIRUS VACCINE. 
FED 
TYPE 
FED 
TYPE 
SUBJECT # 
PREFEEDING 
AB TITRE 
MAXIMAL FOLD 
INCREASE IN 
AB TITRE 
503 61 x5 
513 61* x6 
526 6h X3 
5h6 6b XI* 
» 501 32 x5 
gg 505 16 xli 
gl 5140 16 X6 
511 0 xio 
517 0 X8 
526 0 X8 
553 1021* X2 
501 512 xo 
533 512 XI 
a 570 
571 
li 5142 
512 XO 
512 XI 
6b xo 
Si 55o 
55-3 
6b X2 
6b xl* 
561 32 Xli 
51iO 256 X2 
m 5li7 256 X3 
g g 520 
8 i 571 
256 XI* 
256 xl* 
528 16 x5 
553 6b x5 
506 102b n 
a 52i 
gl 526 
6b X3 
2 56 xl* 
61 X6 
511i 
S H 516 61* 
xi* 
61* X3 
. 
type III poliovirus. 
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METHODS ADD MATERIALS 
This trial was carried out at the S out hour y Training School 
where the Yale Poliomyelitis Study Unit has previously conducted a 
series of trials with Sabin’s type I and type III attenuated polio¬ 
virus vaccines. The risk of encountering wild enterovirus infections, 
including polioviruses, in this type of ’’closed” cottages where the 
present trial was conducted is very slight. In two "closed” cottage^ 
20 children ranging in age from 9-14 years, who had previously re¬ 
ceived Sabin's attenuated type III poliovirus vaccine, either by 
direct feeding or by contact infection in April, 19.58, were fed graded 
doses of the same type III oral poliovirus vaccine. All of these 
children have received liberal amounts of formalinized vaccine and 
were last immunized on October 1, 1959 and January 10, 1961. Prior 
to the 1958 trial one half of these children's homotypic immunity 
had been induced by only killed poliovirus vaccines. At present their 
local intestinal immunity is due to one infection with the type III 
oral poliovirus vaccine (Sabin). The homotypic antibodies of the 
other one half of the present trial group have been induced both by 
natural type III polio infections and the killed poliovirus vaccine. 
Their local intestinal immunity is due to N numbers of natural type 
III poliovirus infections and one infection with the type III oral 
poliovirus vaccine (Sabin). These groups of individuals will be re¬ 
ferred to as the V or U group respectively. 
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Virus: 
Dr. Albert B. Sabin kindly made available the attenuated 
type III poliovirus, KP-34, used in the previous 1958 experiment. (28) 
Using monkey kidney tissu.e culture tubes (10 tubes per log 
step) the virus titred, as calculated by Kaerber’s method, 10^*^ 
rX'CD50 per 0.1 ml prior to feeding. The graded doses of virus iirere 
mixed with a sugared water to insure assimilation of the entire 
dose, .and fed by teaspoon approximately one hour before the noon 
meal. 
Specimens: 
Blood 
Blood specimens were colie cted in vaccuum syringes prior 
to the virus feeding and on the ?th., 28th., and 42th. days there¬ 
after. The serum was separated and frozen on the day of collection. 
Neutralization tests were carried out by the pH colori¬ 
metric method as modified by Melnick and Opton (29), using dispo¬ 
sable plastic panels, and versenized second passage monkey kidney 
cells. Sera were tested at 1:4, 1:8,1:16, 1:32, 1:64, 1:128,1:256, 
1:512, 1:1024 and 1:2048, 1:4096 and 1:8192 using 1 cup per dilution. 
Complement fixation tests (designated hereafter as OF) 
were set up on plastic plates, using the method of -Fulton and Dumbell 
(30) as modified by Black and Melnick (31)* Tissue culture-grown 
antigens of type III poliovirus was used. 
Stools 
When possible daily stool samples were collected for the 
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first 10 days and biweekly thereafter for a period totaling six 
weeks. rJ?hese were stored in the frozen state until prepa.red in the 
routine manner used in this laboratory (32)• After thawing oyer- 
night, a 10 per cent stool suspension was made by mixing 3 gm. of 
stool with 27 ml. of sterile water in a pyrex bottle. After shaking 
for 1 hour on a mechanical shaker the suspension was transferred to 
a lusteroid tube and centrifuged at 3>500 K.P.M. for 1 hour. To the 
supernatant fluid 500 ug. of penicillin and 500 ug. of streptomycin 
per ml. were added; this constituted the inoculum and was stored at 
4 degrees C. until innoculated shortly thereafter. Three oz. culture 
bottles containing trypsinized monolayer monkey kidney tissue grown 
in an out-growth medium containing 0.5 per cent lactalbumin hydro¬ 
lysate, 2 per cent calf serum, 97*5 per cent Hank’s salt solution 
and antibiotics were used through out. 
After removing the media 2 ml of the 10 per cent stool 
suspension was innoculated into each tissue culture bottle. The 
bottles were incubated at 37 degrees C. for 1 1/2-2 hours, after 
which the stool suspension was removed and the cells washed twice 
with 4 ml. of Hank’s balanced salt solution. Six ml. of a main- 
tainance media (32) with twice concentrated bicarbonate was then 
applied. The bottles were read daily after the second day for 1 
weeks and every other day thereafter for a period of 12 days. 
All isolates were identified in neutralization tests set 
up against type III poliovirus as well as a pool of the 3 polio 
types (29). On those positive samples an aliquot of the supernate 
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of the original stool specimen was titrated in log dilutions (3 
tubes per dilution) to determine the amount of virus excreted per 
gm. of stool. 
Rectal Swabs 
In those individuals from whom daily stool specimens were 
not Obtained, rectal swabs were substituted. These swabs were tipped 
with cotton which was moistened with sterile $0 per cent glycerine 
before use. Bach specimen was subsequently placed in a small vial 
containing 2 ml. of Hank’s balanced salt solution. The vials were 
frozen at -20 degrees C. until prepared for innoculation, as follows. 
•The cotton was removed from each swab, then washed and squeezed dry 
20 times in a 2 ml. syringe. The Hank’s solution in which the 
specimens were stored was used for this procedure. This solution 
was then transferred to a lusteroid tube containing 1 ml. of Hank’s 
with an added drop of 3-75 per cent HaHC03 and then centrifuged at 
3,500 R.P.M. for 1 hour. To the supernatant fluid 5^0 ug. of 
penicillin and 500 ug. of streptomycin per ml. were added; this 
constituted the innoculum. 
One ml. of this fluid was then in*oculated in bottles as 
had been done with the stool preparations. The cells and fluid 
were then incubated for approximately 2 hours, after which time 
maintainance media (32) was added to the bottles without removing 
the innoculum or washing the cells. The bottles were first read 
oh the 3rd. day and every other day thereafter for a period of 12 
days. Positive samples were treated in the same way as the positive 
stool samples. 
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RESULTS 
In this trial, as in all the others none of the children 
who received type III oral poliovirus vaccine (Sabin) developed any 
signs of clinical illness. 
The preliminary results of stool excretion and complement 
fixing antibody titer (C.F.) are summarized in Table 4. 
Three of 4 individuals who were fed the largest close of 
virus excreted poliovirus on at least 2 occasions during the first 
postfeeding v/eek. Four subjects fed the lover doses of virus ex¬ 
creted this virus less consistently and generally later, about the 
second postfeeding week, than those feed the largest dose of virus. 
Five of the 7 subjects excreting virus had antibodies 
originally induced by Salk vaccination, with prefeeding titers ranging 
from 128-2043. The 2 originally nati immune subjects who ex¬ 
creted virus had antibody titers of 2048 prior to this virus feeding. 
The rise in C.F. antibodies in subjects No. 5^7 and No. 
526 are suggestive of significant intestinal infection. 
It was observed that 7 of 8 individuals with evidence of 
at least transient intestinal infection live in the same cottage. 
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DISCUSSION 
The seemingly consistent pattern of excretion during the 
first postfeeding week in 3 of 4 individuals who were fed the largest 
virus dose in this trial suggest a reaction similar to that experienced 
"by the subjects fed the largest dose of type I virus in the third type 
I trial (Table 5)* Individuals fed the lower dose of type I poliovirus 
excreted this virus only sporadically (Table 5)> and failed to show 
a homotypic neutralizing antibody response. The preliminary results 
of the present trial suggest a similar response in the individuals 
fed the lower doses of type III poliovirus (Table 4). 
Similar responses to large feedings of both type I and 
type II poliovirus suggest that the relationship between immunity and 
the potential for reinfection in an individual, is relative, a certain 
level of immunity being overcome by a larger dose of virus. 
At the highest virus dose both II and V individuals seemingly 
were intestinally infected, even with homotypic antibody levels as 
high as 2048. 
In the 1958 type III trial, subject No. aged 6 and 
naturally immune with a prefeeding antibody titer of 1024, excreted 
the greatest number (9/10) of positive stools during the first 10 post¬ 
feeding days. Even in the face of such extensive virus excretion a 
significant antibody increase could not be detected. All the other 
N subjects, none with titers higher than 256, experienced at least 
a 3 fold increase in antibody titer. This suggests that a. ceiling 
antibody level is present that cannoii be significantly raised even 
sut 
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by an intensive intestinal infection with the type III poliovirus. 
If such is the case, one might anticipate that the in¬ 
dividuals in the present trial with prefeeding antibody titer of 
2048 (Subjects No. and No. 5^8, Table IV) would not experience 
a significant homotypic antibody response even if found to excrete 
significant amounts of virus. 
It is interesting to note that 5 of 8 subjects showing any 
evidence of infection (No.’s 5^> 5^5 > 5^0, 503 and 5^7) had pre¬ 
feeding antibody titers of 2048. This suggests that with type III 
and unlike type II, circulating homotypic antibody plays little part- 
in preventing virus multiplication within the intestinal tract. The 
sporadic pattern of excretion seen in all reinfected individuals ex¬ 
cept those fed the largest dose of virus suggests that with smaller 
amounts of virus a "local immunity11 induced by previous intestinal 
infections plays a role in preventing virus multiplication in the 
intestinal tract. 
Horstmann et al., in 195?> Ted 4 naturally immune adults 
and 1 child with antibodies induced by killed vaccine, 2 different 
doses of the same type III oral poliovirus vaccine which was used in 
the present study. The results of this 1957 study are briefly sum¬ 
marised in i’igure I. 
Virus Nose Original 
Immune Status 
Virus excreted 
in stools 
Antibody 
rise 
107 *5 N + + 
TCD50 N 4- 4- 
10^*4 N 4 4 
TCD50 N - - 
V + 4* 
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16. 
The reaction of the individuals fed the larger dose in her experiment 
seems similar to that of the N individuals in the type III Southbury 
trial, while the response of individuals to the lower dose of virus 
is more in keeping with the preliminary results of the present trial. 
This suggests that a massive enough dose may he able to overcome 
any degree of previous induced immunity and cause a significant in¬ 
testinal infection. 
SUMMARY 
Twenty children were fed graded doses of Sabin’s oral type 
III poliovirus vaccine. None of the children receiving the vaccine 
showed any signs of clinical illness. 
These results suggest# that with type III as with type I 
poliovirus dosage is an important consideration in initiating re™ 
infection. 
High levels (20U6) of homotypic antibody did not seen to 
play a role in preventing intestinal multiplication of the type III 
poliovirus• 
These results indicate that a ’’local immunity phenomenon1' , 
present in individuals previously exposed to an alimentary infection 
with poliovirus, is effective in preventing reinfection with a homo¬ 
typic poliovirus at lower virus doses, and that a massive dose of polio¬ 
virus may induce a significant intestinal infection reguardless of the 
previous immune status. 
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